MOSCOW (Reuters) - Russia's first potential COVID-19 vaccine will win local regulatory approval in the first half of August and be administered to frontline health workers soon afterwards, a development source close to the matter told Reuters.
A state research facility in Moscow - the Gamaleya Institute - completed early human trials of the adenovirus-based vaccine this month and expects to begin large-scale trials in August.
Already a subscriber? Log in.
Celebrate Merdeka with 50% Off!
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!